Peripal’s Home Dialysis System Receives Marketing Approval


The Swiss medtech startup Peripal AG introduces an innovative auxiliary device for peritoneal dialysis patients. After successfully developing the device in collaboration with ETH Zurich, Peripal AG received the seal of approval to introduce it on the European market. Now patients can undergo home dialysis treatments both more safely and more easily.


The healthcare costs for patients with renal insufficiency amounts to 3 billion euros annually in Germany alone. The costs are disproportionately high at an average of 2-3% of the overall healthcare costs. The number of chronically ill kidney patients will continue to increase markedly in the coming years. In order to counteract skyrocketing costs, the healthcare industry must focus increasingly on at-home therapies, which are significantly more cost-efficient than hospital dialysis treatments. In addition, the majority of all patients and their family members would prefer therapy in the comfort of their own homes, thereby increasing their quality of life. The risk of infection, increasing age, and the associated limitations, however, are some of the reasons why ultimately very few patients choose to perform home dialysis. This is where the Zurich-based company Peripal AG comes in. "We developed our device in close collaboration with dialysis patients, so logically it is geared toward the needs of the people who actually use it. The whole team is really proud of this", says CEO Dr. Sandra Neumann. PeriSafe, which can be used on peritoneal dialysis patients starting immediately, prevents infections and substantially simplifies the therapy process. PeriSafe is addressing the two major complications in Peritoneal Dialysis connection: the infection risk and the complexity of the therapy handling. The most delicate therapy step, the manual connection of the transfer set and the dialysis bag system, is performed inside of the protected device. This could lead to an infection decrease. The standardization and the simplified handling could lead to an easier therapy learning and could reduce the training time for the patient, the relatives and nurses. As a result, patients who were not yet eligible for treatment also have the chance to undergo peritoneal dialysis. Today approximately 10% of all patients worldwide perform dialysis at home, though experts and scientific studies conclude that the potential number of such patients may be as high as 35%. The new device is an important step in promoting home dialysis, a process which has long been demanded and supported by health departments and health insurances in numerous countries. (Press release - SK)